By Vitaliy Katsenelson I sang love serenades for Abbott Labs’ (ABT) stock for a long time. Call me materialistic, but my love for stocks is not ‘til death do us part,’ it is conditional of fundamentals staying intact and of valuation – it has to be undervalued. Abbott Labs’ fundamentals have improved over the last couple [...]
It seems that 2007 should be a brighter year for Johnson & Johnson (NYSE JNJ). In 2006 the company faced major drug expirations which dampened revenue growth. I really like the Pfizer’s (PFE) consumer business acquisition. Despite having a fairly good product line, Pfizer Inc was a pharmaceutical company that happened to have consumer products which came [...]
I am not a buyer of Abbott Labs(ABT) at this price, as the margin of safety has been depleted by the latest stock appreciation. But I like its latest transaction with General Electric (NYSE GE). Abbott proved to be a shrewd buyer and seller. It played Johnson & Johnson (JNJ), Guidant (GDT) and Boston Scientific (BSX) masterfully [...]